Article Text

PDF
Octreotide for endocrine tumours

Abstract

Octreotide (Sandostatin - Sandoz) is a synthetic octapeptide analogue of somatostatin. Like somatostatin it inhibits peptide release from endocrine secreting tumours of the gastroenteropancreatic (GEP) system and the pituitary. Octreotide is licensed for the treatment of patients with the GEP tumours, VIPoma, glucagonoma and carcinoid, but not, as yet, for acromegaly and thyrotoxicosis secondary to pituitary adenoma.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.